Description: Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Home Page: www.atossatherapeutics.com
107 Spring Street
Seattle,
WA
98104
United States
Phone:
206 588 0256
Officers
| Name | Title |
|---|---|
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, CEO & President |
| Ms. Heather Rees CPA | Chief Financial Officer & Principal Accounting Officer |
| Ms. Delly Behen P.H.R. | Senior Vice President of Administration & HR |
| Mr. Eric Van Zanten | Vice President of Investor & Public Relations |
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer |
Exchange: STU
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0639 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 12 |